Sales are generated mainly from the lead product Zubsolv® for the treatment of opioid use disorder. Other revenues come from out-licensing of Zubsolv or other drugs commercialized by partners, such as Abstral® for breakthrough cancer pain and Edluar® for insomnia. Revenues from the lead product have enabled investments in research and development as well as in digital mental health programs. Investments in these assets are expected to generate future revenues from sales, including upfront and milestone payments, and royalty.
- Commercialization of pharmaceuticals and digital mental health programs in the US
- Product out-licensing
- Co-development
- Supply chain